Cumberland Pharmaceuticals Q1 Earnings Call Highlights
Both Kazimi and CFO John M. Hamm pointed to the transaction’s expected tax impact. Kazimi said the company estimates resulting income taxes will be “modest,” which he said would allow the net consideration to significantly strengthen Cumberland’s balance sheet. Hamm added that Cumberland has “over $53 million in tax net operating loss carryforwards” and that the assets involved in the transaction have a “tax basis of $30 million,” supporting the company’s view that taxes should be modest.Kazimi said Cumberl ...